Navigation Links
Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Date:11/2/2010

BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, presented an abstract at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions on November 2, 2010 in Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition of Factor IXa by Subcutaneous RB006 with Active Reversal: First-in-Human Experience with the REG2 System."

The REG2 system is intended for use in venous thrombosis indications.  This initial Phase 1 study was the first successful subcutaneous application of an aptamer in humans.  It demonstrated that a single subcutaneous injection of RB006 (aka pegnivacogin) resulted in dose-dependent inhibition of Factor IXa with effects that persisted longer than one week after injection. The data is promising for future development of REG2.

The abstract is coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC and William Wargin, Ph.D., President of PK-PM Associates, LLC.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at the ... Cancer Institute have received an $8 million grant from ... of photodynamic light therapy (PDT) in patients with malignant ... most often manifests itself in the lining of the ... asbestos. The grant will fund a clinical trial and ...
(Date:7/9/2014)... metabolism of stromal support cells and immune cells ... types in the development of diseases could open ... That was the conclusion of a review article by ... journal Nature . , Prof. Peter Carmeliet: "Consider ... metabolism of cancer cells has been examined in minute ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... Cup highlights, Brian Williams refreshing old school rap classics, ... railings. A University of Colorado Cancer Center study published ... YouTube also allows researchers, journals, and health advocates to ... cancer and prevention. , "No matter what field you,re ... communicate around the world," says Chante Karimkhani, MD candidate ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... , MINNEAPOLIS, June 9 Nonin Medical, Inc., ... history today by announcing the world,s first Bluetooth(R)-enabled ... now certified as compliant to the Continua(TM) Version ... Device Profile (HDP) and ISO/IEEE 11073 data protocol, ...
... from the Virginia Bioinformatics Institute (VBI) at Virginia Tech ... that allows them to profile in detail complex cellular ... to look at how the levels of proteins change ... hormones or cancer drugs like tamoxifen. VBI Assistant ...
... June 9 /PRNewswire-FirstCall/ -- Apria Healthcare Group ... ) (NYSE: PER ) today announced an ... to Apria Healthcare a range of healthcare information technology solutions, ... as well as consulting services. The term of the ...
... Resort Sponsors Scottish-Themed Charity Event , , OAK BROOK, Ill., June 9 ... night at the Oak Brook Hills Marriott Resort in Illinois. From 4:30 p.m. ... will be hosting the Oak Brook Hills Golf Classic to benefit the ... will feature: , , , ...
... you are getting full when eating a large meal? New ... may partially explain why severely obese individuals may not feel ... of food they consume during a meal. Researchers led ... and Diabetes Research Center focused on habituation, or the idea ...
... researchers determine that race has no bearing on life expectancy ... Older adults with mild cognitive impairment or Alzheimer,s disease have ... risk of death is no greater for whites or blacks, ... at Rush University Medical Center in Chicago, contradicts earlier information ...
Cached Medicine News:Health News:Nonin Medical, Inc. Announces the First Bluetooth(R) Continua(TM) Certified Product 2Health News:VBI researchers develop new method for breast cancer biomarker discovery 2Health News:Apria Healthcare Awards Technology Solutions Contract to Perot Systems 2Health News:Apria Healthcare Awards Technology Solutions Contract to Perot Systems 3Health News:Oak Brook Hills Golf Classic to Benefit the Children's Miracle Network 2Health News:Physiological response may explain why some severely obese patients overeat 2Health News:Alzheimer's and Even Mild Dementia Hasten Death 2
West 2 periosteal elevators....
Semb periosteal elevators....
Williger periosteal elevators....
Lambotte periosteal elevators....
Medicine Products: